Ekso Bionics Holdings GAAP EPS of -$0.29, revenue of $41.5M beats by $23.4M (CHRN:NASDAQ)
Ekso Bionics Holdings reported Q1 GAAP EPS of -$0.29 and revenue of $41.5M, exceeding estimates by $23.4M. Revenue grew 1127.8% year-over-year. Adjusted EBITDA was $5.9M, down from $9.4M in the prior year quarter.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public data on Q1 performance, offering traders fresh information to assess valuation.
Market read
First‑report earnings for a micro‑cap biotech; relevance driven by revenue surprise rather than profitability.
What to watch
Potential upcoming regulatory approvals or partnership announcements could change outlook.
Background
Ekso Bionics is a developer of wearable exoskeletons for medical and industrial use.
Ticker impact
Q1 GAAP EPS of -$0.29 and revenue of $41.5M, a 1127.8% YoY increase, beating estimates by $23.4M.
likely modest downside as investors weigh loss against revenue growth
Loss per share signals ongoing cost issues, but the revenue surge could attract upside speculation.
Market effects
Highlights rapid growth potential in the exoskeleton/medical device sector.
Limited to U.S. small‑cap investors; no broader regional effect.
Minimal global impact beyond niche biotech/medtech investors.
Counterpoint
Revenue beat may be unsustainable; focus on cash burn and loss per share.
Key entities
- CompanyEkso Bionics Holdings
Publicly traded exoskeleton manufacturer (NASDAQ: CHRN).


